Seattle、WAにおける乳がんの臨床試験
Seattleとその周辺地域（約30マイル以内）の拠点で、乳がんに関する39件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- University of Washington, Fred Hutchinson Cancer Center, Seattle
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- 他1件
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
被験者募集中第1相
- Fred Hutchinson Cancer Center, Seattle
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
被験者募集中第1/2相
- Fred Hutchinson Cancer Research Center, Seattle
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
被験者募集中第1相
- Fred Hutchinson Cancer Research Center, Seattle
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
被験者募集中第3相
- Fred Hutchinson Cancer Center ( Site 0069), Seattle
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
被験者募集中第2相
- Fred Hutchinson Cancer Center, Seattle
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Swedish Medical Center, Seattle
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
被験者募集中第3相
- Clinical Trial Site, Seattle
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
被験者募集中
- Fred Hutch Cancer Center, Seattle
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
被験者募集中第3相
- Swedish Medical Center, Seattle
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
被験者募集中
- University of Washington, Seattle
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
被験者募集中第3相
- Swedish Medical Center, Seattle
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
被験者募集中第3相
- Virginia Mason Medical Center, Seattle
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
- 他1件
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
被験者募集中第1相
- Fred Hutchinson Cancer Research Center, Seattle
A Phase 1/1b Study of IAM1363 in HER2 Cancers
被験者募集中第1相
- Fred Hutchinson Cancer Center, Seattle
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
被験者募集中第3相
- Swedish Cancer Institute - Issaquah, Seattle
- Swedish Cancer Institute, Seattle
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
被験者募集中第3相
- Virginia Mason Medical Center, Seattle
- Swedish Medical Center-Ballard Campus, Seattle
- Fred Hutchinson Cancer Center, Seattle
- 他5件
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
被験者募集中第1/2相
- Fred Hutch Cancer Research, Seattle
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
被験者募集中第2相
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
被験者募集中
- Swedish Cancer Institute, Seattle
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- Swedish Cancer Institute, Seattle
E-Mindfulness Approaches for Living After Breast Cancer
被験者募集中第3相
- Saint Joseph Medical Center Hematology and Oncology - Silverdale, Silverdale · 17マイル先
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
被験者募集中第1相
- University Of Washington, Seattle
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
被験者募集中第2相
- University of Washington School of Medicine, Seattle
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
被験者募集中第1/2相
- Fred Hutchinson Cancer Center, Seattle
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Fred Hutchinson Cancer Center, Seattle
[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
被験者募集中第1/2相
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
被験者募集中第3相
- Fred Hutchinson Cancer Center, Seattle
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
被験者募集中第3相
- Fred Hutchinson Cancer Center, Seattle
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
被験者募集中第3相
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-First Hill, Seattle
- Saint Michael Cancer Center, Silverdale · 17マイル先
Quantitative MRI Assessment of Breast Cancer Therapy Response
被験者募集中観察研究
- University of Washington, Seattle
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
被験者募集中第2相
- University of Washington, Seattle
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
被験者募集中第1/2相
- Fred Hutchinson Cancer Center, Seattle
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
被験者募集中観察研究
- Kaiser Permanente Washington, Seattle
- Swedish Medical Center-First Hill, Seattle
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
被験者募集中第1相
- Fred Hutchinson Cancer Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Seattle
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
被験者募集中第3相
- FHCC South Lake Union, Seattle
- Swedish Medical Center-First Hill, Seattle
- University of Washington Medical Center - Montlake, Seattle
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
被験者募集中観察研究
- Swedish Cancer Institute, Seattle
- Seattle Cancer Care Alliance, Seattle
他の都市における乳がんの試験
- New York City, NY134件の研究
- Houston, TX126件の研究
- Boston, MA111件の研究
- Nashville, TN80件の研究
- Los Angeles, CA72件の研究
- Edison, NJ68件の研究
- St. Louis, MO64件の研究
- Durham, NC63件の研究
- Queens, NY63件の研究
- Chicago, IL58件の研究
- Philadelphia, PA56件の研究
- Dallas, TX55件の研究
Seattleにおける他の研究
- 非小細胞肺癌53件の研究
- がん（全種類）49件の研究
- 前立腺がん42件の研究
- 急性骨髄性白血病40件の研究
- 転移性癌39件の研究
- 大腸癌34件の研究
- 肺がん33件の研究
- 卵巣がん30件の研究
- 多発性骨髄腫22件の研究
- 骨髄異形成症候群21件の研究
- 急性リンパ性白血病21件の研究
- 膀胱癌21件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。